Table 2.
Reasons for switching patients from VKA to NOAC according to NOAC indication, as reported by the attending physician (multiple reasons possible)
| Reasons for switching from VKA to NOAC | Transition in SPAF (n = 568) n (%) | Transition in VTE (n = 148) n (%) | P value |
|---|---|---|---|
| Unstable INR | 331 (58.3) | 87 (58.8) | 0.926 |
| Bleeding complications | 103 (18.1) | 21 (14.2) | 0.275 |
| Thromboembolic complications | 15 (2.6) | 5 (3.4) | 0.582 |
| Repeated falls | 73 (12.9) | 8 (5.4) | 0.009 |
| Others | 207 (36.4) | 57 (38.5) | 0.634 |
Results of statistical significance are in bold. Abbreviations are as follows: INR, international normalized ratio; NOAC, novel oral anticoagulants; SPAF, stroke prevention in atrial fibrillation; VKA, vitamin-K antagonists; VTE, venous thromboembolism.